Spandana Sphoorty Financial Limited has informed the Exchange regarding Outcome of Board Meeting held on May 30, 2025.
SPANDANA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Spandana Sphoorty's board approved audited standalone and consolidated financial results for Q4 and FY ended March 31, 2025, with B S R & Co. LLP issuing an unmodified opinion. The company reported a steep net loss of ₹956.74 crore for FY25 versus a profit of ₹467.88 crore in FY24, with Q4 FY25 alone posting a loss of ₹410.19 crore. Total expenses nearly doubled to ₹3,519 crore driven by impairment on financial instruments of ₹1,863 crore, including technical write-offs of ₹1,555 crore amid microfinance industry stress. Loan book shrank from ₹10,567 crore to ₹5,554 crore, while CRAR remained healthy at 36.31%. The board also approved a ₹4,000 crore NCD issuance limit on private placement (subject to shareholder approval) and constituted a Fund-Raising Committee to evaluate the earlier-approved ₹750 crore equity raise via QIP or other modes.
The sharp swing to loss and ~47% contraction in loan book signal serious asset-quality stress, which may pressure the stock in the near term. However, a strong CRAR of 36.31%, healthy liquidity buffer, and planned capital infusion of up to ₹750 crore (plus up to ₹4,000 crore in NCDs) provide confidence capital for recovery, though shareholders should watch Q1 FY26 trends and the June 30, 2025 RBI qualifying-assets deadline closely.